루타테라, 신경내분비종양 질환 경과 바꾼 게임 체인저 – 의약뉴스
직장 신경내분비종양에 대한 이해-디지틀조선TV
“신경내분비종양, 관리 가능한 암… 완치 강박 버리고 ‘건강한 共存(공존)’ 모색해야” – 헬스조선
[Health&] “비특이적인 신경내분비종양, 소마토스타틴 유사체로 병 진행 억제” | 중앙일보
“개정된 신경내분비암 항암요법, 진료 현장에 더 알려져야” < 종합병원 < 메디시안 < 기사본문 – 메디파나뉴스
“숨은 암도 찾아낸다”… 희귀암 ‘신경내분비종양’ 방사성 검사로 진단 – 코메디닷컴
Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 study | Nature Communications
Cabozantinib in Grade 3 Neuroendocrine Tumors | OncLive
GLP-1 Agonists: Theoretical Risks for Neuroendocrine Tumors | Targeted Oncology – Immunotherapy, Biomarkers, and Cancer Pathways
Short Distal Resection Margin Does Not Increase Recurrence Risk After R0 Resection for Rectal Neuroendocrine Tumors: A Single‐Institution Retrospective Study of 208 Patients – Sato – 2026 – Annals of Gastroenterological Surgery – Wiley Online Library
Neuroendocrine Neoplasms of the Gastrointestinal Tract: Morphology, WHO 2022 Grading, and Prognostic Perspectives | Cureus
Cushing Linked to Poor Prognosis in Neuroendocrine Neoplasms
DLL3 as an Emerging Biomarker and Therapeutic Target | OncLive
